Metformin Glycinate

Summary

Metformin Glycinate (CHEMBL2108299) is a phase-3 clinical-stage unknown; indicated across 3 conditions including type 2 diabetes mellitus and diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108299
Name	Metformin Glycinate
Type	Unknown
Max phase	3

Also known as: DMMET-01, Glicinato de metformina, Glycinate de metformine, Metformin glycinate, METFORMIN GLYCINATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
diabetes mellitus	2	MONDO:0005015	EFO:0000400
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	3
PHASE2/PHASE3	2
PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00940472	PHASE2/PHASE3	COMPLETED	Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients
NCT01386671	PHASE3	COMPLETED	Metformin Glycinate on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes
NCT02064881	PHASE2/PHASE3	UNKNOWN	Efficacy Study of Metformin Glycinate on Postprandial Lipemia
NCT04943692	PHASE3	SUSPENDED	Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
NCT00940797	PHASE2	COMPLETED	Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients (CLAMP)
NCT04625985	PHASE2	COMPLETED	Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.
NCT04626089	PHASE2	WITHDRAWN	Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
NCT00960882	PHASE1	COMPLETED	Gastric Tolerability and Pharmacokinetics of DMMET-01

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).